Cargando…

Src Inhibitors, PP2 and Dasatinib, Increase Retinoic Acid-Induced Association of Lyn and c-Raf (S259) and Enhance MAPK Dependent Differentiation of Myeloid Leukemia Cells

All-trans-retinoic-acid (ATRA)-induced differentiation of human myeloid leukemia cells is characterized by persistent MAPK signaling. Fragmentary data suggests Src family kinase (SFK) inhibitors enhance differentiation and thus have potential therapeutic value. The present study shows that SFK inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Congleton, Johanna, MacDonald, Robert, Yen, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310950/ https://www.ncbi.nlm.nih.gov/pubmed/22182854 http://dx.doi.org/10.1038/leu.2011.390

Ejemplares similares

The Src-Family Kinase Inhibitor PP2 Rescues Inducible Differentiation Events in Emergent Retinoic Acid-Resistant Myeloblastic Leukemia Cells
por: Jensen, Holly A., et al.
Publicado: (2013)

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line
por: Okabe, Seiichi, et al.
Publicado: (2011)

Dasatinib Inhibits Lyn and Fyn Src-Family Kinases in Mast Cells to Suppress Type I Hypersensitivity in Mice
por: Lee, Dajeong, et al.
Publicado: (2020)

Rapid Molecular Response to Dasatinib in a Pediatric Relapsed Acute Lymphoblastic Leukemia With NCOR1-LYN Fusion
por: Dai, Hai-Ping, et al.
Publicado: (2020)

Dasatinib targets c-Src kinase in cardiotoxicity
por: Elmadani, Manar, et al.
Publicado: (2023)

LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients
por: Kim, Yu Jin, et al.
Publicado: (2016)

Dasatinib in chronic myeloid leukemia: a review
por: Aguilera, Dolly G, et al.
Publicado: (2009)

Systematic review of dasatinib in chronic myeloid leukemia
por: Breccia, Massimo, et al.
Publicado: (2013)

The role of dasatinib in the management of chronic myeloid leukemia
por: Chen, Runzhe, et al.
Publicado: (2015)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
por: Lima, Lisa M, et al.
Publicado: (2010)

Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018)

Expanding dasatinib beyond KIT in acute myeloid leukemia
por: Welch, John S.
Publicado: (2020)

Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients
por: Roseweir, Antonia K., et al.
Publicado: (2016)

ACLY is the novel signaling target of PIP(2)/PIP(3) and Lyn in acute myeloid leukemia
por: Basappa, Johnvesly, et al.
Publicado: (2020)

Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
por: Haslam, Sonya
Publicado: (2005)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
por: Hong, Ji Hyung, et al.
Publicado: (2015)

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
por: Keskin, Dilek, et al.
Publicado: (2016)

Skin lesions in chronic myeloid leukemia patients during dasatinib treatment
por: Tarantini, Francesco, et al.
Publicado: (2019)

Diagnostic Pitfalls of Chylothorax After Dasatinib Treatment of Chronic Myeloid Leukemia
por: Kelly, Ryan L., et al.
Publicado: (2022)

Lyn, Jak2, and Raf-1 Kinases Are Critical for the Antiapoptotic Effect of Interleukin 5, whereas only Raf-1 Kinase Is Essential for Eosinophil Activation and Degranulation
por: Pazdrak, Konrad, et al.
Publicado: (1998)

Src family kinases Fyn and Lyn are constitutively activated and mediate plasmacytoid dendritic cell responses
por: Dallari, S., et al.
Publicado: (2017)

Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy
por: Serpa, Mariana, et al.
Publicado: (2010)

Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case
por: Monge, Katia Sotelo, et al.
Publicado: (2015)

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016)

Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia
por: Makimoto, Go, et al.
Publicado: (2022)

Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia
por: Adattini, Josephine A., et al.
Publicado: (2023)

An Effective Model of the Retinoic Acid Induced HL-60 Differentiation Program
por: Tasseff, Ryan, et al.
Publicado: (2017)

Retinoic Acid Receptors in Acute Myeloid Leukemia Therapy
por: di Martino, Orsola, et al.
Publicado: (2019)

Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
por: Maat, Zakaria, et al.
Publicado: (2021)

“Lyn”king Emphysema and Cancer Development: Insights from Src Family Kinase Gain-of-Function Models
por: Suresh, Karthik
Publicado: (2023)

Proposal P259
por: Pretzl, Klaus P
Publicado: (1991)

Discovery of fermium-259
por: Hoffman, D C, et al.
Publicado: (1976)

Successful Pregnancy and Delivery in a Patient with Chronic Myeloid Leukemia while on Dasatinib Therapy
por: Conchon, Monika, et al.
Publicado: (2010)

Dasatinib Induced Avascular Necrosis of Femoral Head in Adult Patient with Chronic Myeloid Leukemia
por: Yassin, Mohamed A, et al.
Publicado: (2015)

Dasatinib-Induced Rhabdomyolysis in a 33-Year-Old Patient with Chronic Myeloid Leukemia
por: Joel Chandranesan, Andrew Stevenson, et al.
Publicado: (2018)

Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: A case report
por: Pilalas, Dimitrios, et al.
Publicado: (2020)

Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib
por: SahBandar, Ivo N., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sn5ffo11td3661m4bm51gqonou